Patents by Inventor Philippe Hammel

Philippe Hammel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal Olfml-3 antibodies and uses thereof
    Patent number: 10808026
    Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 20, 2020
    Assignee: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • MODULATION OF SRPX2-MEDIATED ANGIOGENESIS
    Publication number: 20180214546
    Abstract: The present invention relates to nucleic acids and antibodies against SRPX2 and SRPX2 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the SRPX2 antagonists or agonists, respectively.
    Type: Application
    Filed: January 5, 2018
    Publication date: August 2, 2018
    Applicant: Research Development Foundation
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS
    Publication number: 20160333084
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 17, 2016
    Applicant: Research Development Foundation
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS
    Publication number: 20150299306
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Application
    Filed: July 7, 2015
    Publication date: October 22, 2015
    Applicant: Research Development Foundation
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • Methods and compositions for modulation of Olfml3 mediated angiogenisis
    Patent number: 9096662
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 4, 2015
    Assignee: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • MONOCLONAL OLFML-3 ANTIBODIES AND USES THEREOF
    Publication number: 20150098947
    Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 9, 2015
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • Methods and compositions for modulation of Olfml3 mediated angiogenesis
    Patent number: 8663637
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: March 4, 2014
    Assignee: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS
    Publication number: 20130034493
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Application
    Filed: July 25, 2012
    Publication date: February 7, 2013
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • MODULATION OF OLFML-3 MEDIATED ANGIOGENESIS
    Publication number: 20110287088
    Abstract: The present invention relates to nucleic acids and antibodies against Olfml-3 and Olfml-3 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the Olfml-3 antagonists or agonists, respectively.
    Type: Application
    Filed: November 30, 2009
    Publication date: November 24, 2011
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
  • MODULATION OF SRPX2-MEDIATED ANGIOGENESIS
    Publication number: 20110052677
    Abstract: The present invention relates to nucleic acids and antibodies against SRPX2 and SRPX2 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the SRPX2 antagonists or agonists, respectively.
    Type: Application
    Filed: March 3, 2009
    Publication date: March 3, 2011
    Applicant: Research Development Foundation
    Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel